Accelerated pathways shift the proof of clinical benefit from pre-market trials to post-marketing requirements.
To expedite access to critical therapies, regulatory frameworks are granting early market entry based on surrogate biomarkers while deferring the rigorous verification of clinical efficacy to post-marketing confirmatory trials.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
A developer is seeking accelerated approval for a rare neurodegenerative gene therapy based on a Phase I/II package, deferring final clinical verification to a post-market study.
Tzield secured early market access based on a surrogate biomarker, leaving the definitive proof of clinical benefit to the ongoing BETA-PRESERVE confirmatory study.
Early filing approval was granted on a 3-year data package, with full clinical verification postponed to a planned confirmatory study.
The FDA bypassed standard pre-market requirements by allowing a gene therapy to proceed to a BLA filing with Phase I/II data on the condition of executing a post-market confirmatory trial.
The FDA granted accelerated approval based on the surrogate of reduced cornstarch intake, requiring a ten-year monitoring program to verify actual clinical efficacy.
The therapy was cleared based on a surrogate protein biomarker, with full approval contingent on subsequent kidney function clinical verification.
The FDA granted early market entry using a molecular surrogate endpoint, deferring long-term survival verification to the ongoing EXCALIBER-RRMM confirmatory trial.
Replimune's cutaneous melanoma therapy entered the market via accelerated approval based on early response rates, leaving final survival proof to a post-marketing trial.
The regulatory framework allows a gene therapy developer to file for market access using early phase data, shifting the definitive proof of efficacy to a post-approval confirmatory study.
The FDA utilized MRD-negativity as a surrogate endpoint to grant accelerated approval, deferring traditional progression-free survival outcomes to confirmatory studies.
Ultragenyx's rare metabolic gene therapy won early approval based on a surrogate dietary reduction, deferring long-term clinical verification to a post-marketing follow-up program.